Sun Pharmaceutical Industries Limited — Updates, 04-02-2025: Press Release

Sun Pharmaceutical Industries, in collaboration with Philogen S.p.A., successfully completed patient enrollment in the Phase III FIBROSARC trial for Soft Tissue Sarcoma (STS). This marks a significant advancement in their Fibromun program, with key readouts expected between March and June 2025. The trials are progressing as planned across Europe and the U.S., and the rapid enrollment in the Glioblastoma trials is noteworthy, with completion anticipated earlier than expected. Fibromun, a biopharmaceutical product, combines the L19 antibody with tumor necrosis factor to target neoplastic tissues, indicating a strong potential for treating advanced soft tissue sarcomas and glioblastoma. With ongoing pivotal studies hinting at eventual registration opportunities, investors should watch closely the trial outcomes in the coming months for potential growth in Sun Pharma’s portfolio, particularly in oncology.